58 studies found for:    "Carcinoid syndrome"
Show Display Options
RSS Create an RSS feed from your search for:
"Carcinoid syndrome"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Withdrawn Study of Panitumumab in the Treatment of Carcinoid Syndrome
Condition: Carcinoid Syndrome
Intervention: Drug: Panitumumab
2 Completed Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome
Condition: Symptoms of Carcinoid Syndrome
Interventions: Drug: Low Dose LX1606 - Day 1 (start);   Drug: Mid-low dose LX1606 - Day 15 (start);   Drug: Mid-high dose LX1606 - Day 29 (start);   Drug: High dose LX1606 - Day 43 (start);   Drug: 4-Week Open Label Dose Extension;   Drug: 72-Week Open Label Dose Extension
3 Terminated Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome
Condition: Malignant Carcinoid Syndrome
Interventions: Drug: lanreotide Autogel (somatostatin analogue);   Drug: Sandostatin long acting release (LAR) Depot (somatostatin analogue)
4 Completed Effects of Serotonin Excess on Bone in Carcinoid Syndrome
Condition: Carcinoid Syndrome
Intervention:
5 Recruiting Telotristat Etiprate for Carcinoid Syndrome Therapy
Condition: Carcinoid Syndrome
Interventions: Drug: Telotristat etiprate tablets (250 mg);   Drug: Placebo
6 Terminated Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome
Condition: Carcinoid Syndrome
Intervention: Drug: Octreotide
7 Active, not recruiting An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome
Condition: Carcinoid Syndrome
Interventions: Drug: Somatuline Depot (lanreotide);   Drug: placebo
8 Terminated Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome
Condition: Carcinoid Syndrome
Intervention: Drug: BIM 23A760
9 Recruiting TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)
Condition: Carcinoid Syndrome
Interventions: Drug: Telotristat etiprate tablets (250 mg);   Drug: Placebo tablets
10 Completed A Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of Diarrhea
Condition: Neuroendocrine Tumour (NET) With Carcinoid Syndrome
Intervention:
11 Recruiting Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms
Condition: Carcinoid Syndrome
Intervention: Drug: Telotristat etiprate tablets (250 mg)
12 Completed Study of LX1606 in Subjects With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy
Condition: Carcinoid Syndrome
Interventions: Drug: Low Dose Part 1;   Drug: Mid-Low Dose Part 1;   Drug: Mid-High Dose Part 1;   Drug: High Dose Part 1;   Drug: Part 2 Expanded Cohort;   Drug: Placebo;   Drug: Open Label Dose Extension;   Drug: Open Label Extension 2;   Drug: Open Label Extension 3
13 Completed An Open-label Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]-Telotristat Etiprate in Males
Condition: Carcinoid Syndrome
Intervention: Drug: 500 mg [14C]-LX1606
14 Completed
Has Results
Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor
Conditions: Carcinoid Tumor;   Malignant Carcinoid Syndrome
Interventions: Drug: Octreotide;   Drug: Placebo;   Drug: Everolimus
15 Recruiting P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid Syndrome
Condition: Neuroendocrine Carcinoma
Intervention: Drug: Octreotide LAR
16 Completed Azilect + Antidepressant Chart Review
Condition: Serotonin Syndrome
Interventions: Drug: Group R+AD Rasagiline + Antidepressant;   Drug: Group R Rasagiline;   Drug: Group AD Anti-PD + Antidepressant
17 Unknown  Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
Conditions: Anal Cancer;   Carcinoma of the Appendix;   Colorectal Cancer;   Extrahepatic Bile Duct Cancer;   Gallbladder Cancer;   Gastric Cancer;   Gastrointestinal Carcinoid Tumor;   Liver Cancer;   Nausea and Vomiting;   Pancreatic Cancer;   Primary Peritoneal Cavity Cancer;   Small Intestine Cancer
Interventions: Drug: palonosetron hydrochloride;   Other: placebo
18 Completed Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer
Conditions: Brain and Central Nervous System Tumors;   Breast Cancer;   Gastrointestinal Carcinoid Tumor;   Islet Cell Tumor;   Lung Cancer;   Lymphoma;   Melanoma (Skin);   Neoplastic Syndrome
Intervention: Radiation: yttrium Y 90-edotreotide
19 Completed Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors
Conditions: Metastatic Gastrointestinal Carcinoid Tumor;   Recurrent Gastrointestinal Carcinoid Tumor;   Regional Gastrointestinal Carcinoid Tumor
Interventions: Biological: PEG-interferon alfa-2b;   Biological: bevacizumab;   Other: laboratory biomarker analysis
20 Suspended Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
Conditions: Adult Primary Hepatocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Endometrial Papillary Serous Carcinoma;   Localized Unresectable Adult Primary Liver Cancer;   Metastatic Gastrointestinal Carcinoid Tumor;   Ovarian Carcinosarcoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mixed Epithelial Carcinoma;   Ovarian Papillary Serous Carcinoma;   Pancreatic Alpha Cell Adenoma;   Pancreatic Alpha Cell Carcinoma;   Pancreatic Beta Islet Cell Adenoma;   Pancreatic Beta Islet Cell Carcinoma;   Pancreatic Delta Cell Adenoma;   Pancreatic Delta Cell Carcinoma;   Pancreatic G-cell Adenoma;   Pancreatic G-cell Carcinoma;   Pancreatic Polypeptide Tumor;   Pulmonary Carcinoid Tumor;   Recurrent Adult Primary Liver Cancer;   Recurrent Endometrial Carcinoma;   Recurrent Fallopian Tube Cancer;   Recurrent Gastrointestinal Carcinoid Tumor;   Recurrent Islet Cell Carcinoma;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer;   Regional Gastrointestinal Carcinoid Tumor;   Stage IIIA Endometrial Carcinoma;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIA Primary Peritoneal Cavity Cancer;   Stage IIIB Endometrial Carcinoma;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIB Primary Peritoneal Cavity Cancer;   Stage IIIC Endometrial Carcinoma;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Primary Peritoneal Cavity Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Epithelial Cancer;   Stage IV Primary Peritoneal Cavity Cancer;   Stage IVA Endometrial Carcinoma;   Stage IVB Endometrial Carcinoma;   Uterine Carcinosarcoma
Interventions: Drug: temsirolimus;   Biological: bevacizumab

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years